No Data
The Growth 250 dropped significantly, with selling ahead due to worsening sentiment = Emerging Markets, 14th.
The Tokyo Stock Exchange Growth Market 250 Index has fallen significantly. Investor sentiment is deteriorating due to the overall decline of the Tokyo market. Ispace <9348.T>, Chordia Therapeutics <190A.T>, Cellseed <7776.T>, and others have decreased. On the other hand, N.P.C. <6255.T>, which had good earnings, reached a daily limit up. In recent IPOs, Visumo <303A.T> has fallen for four consecutive days. In the standard category, Sumishin SBI Net Bank <7163.T>.
Chordia Therapeutics---Rogosecib has been accepted for rare disease designation in the USA.
On the 10th, Chordia Therapeutics <190A> announced that its CLK inhibitor drug rogocekib has received rare disease designation as a treatment for relapsed refractory acute myeloid leukemia (AML) in the USA. This rare disease designation is a special approval system by the USA Food and Drug Administration (FDA) that supports the acceleration of the development of drugs for rare diseases. Rogosekib is for the treatment of relapsed acute myeloid leukemia.
Chordia Therapeutics: Summary of financial results for the 1st quarter of the fiscal year ending August 2025 [Japanese GAAP] (unconsolidated)
Kasumigaseki Capital, Asahi Chemicals, Toho, Bunkyo HD (14th)
※ The above Calendar is merely a schedule and may be subject to change due to corporate circumstances. --------------------------------------- January 14 (Tuesday) <135A> VRAIN <1377> Sakata Seed <138A> Hikari Food Service <1401> mbs <1407> West HD <1418> Interlife <1419> Tama Home <1430> 1st Co.
Volume change rate ranking (9 o'clock time slot) - Sankoh Gosei, BTM, ETC rank in.
In the ranking of Volume change rates, by comparing the average Volume over the last five days with the Volume on the day of delivery, it is possible to understand the trends of market participants' interests, etc. ■ Top Volume Change Rates [As of January 10th, 9:32] (Comparison with the average Volume over the last five days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <4530> Hisamitsu Pharmaceutical 502000 107185.08 183.01% 0.1088% <7888> Sanko Gosei 5
Chordia Therapeutics Secures Orphan Drug Designation for Rogocekib in the U.S.